- Home
- ACDC vs COLL Comparison
ACDC vs COLL Comparison
Compare ACDC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACDC | COLL |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 1.5B |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ACDC | COLL |
|---|---|---|
| Price | $3.93 | $49.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.83 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 1.3M | 550.4K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | ★ $1,960,000,000.00 | $757,067,000.00 |
| Revenue This Year | N/A | $26.35 |
| Revenue Next Year | N/A | $3.67 |
| P/E Ratio | ★ N/A | $30.35 |
| Revenue Growth | N/A | ★ 26.34 |
| 52 Week Low | $3.08 | $23.23 |
| 52 Week High | $10.70 | $49.92 |
Technical Indicators
Market Signals| Indicator | ACDC | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 72.75 |
| Support Level | $3.87 | $47.83 |
| Resistance Level | $4.64 | $49.92 |
| Average True Range (ATR) | 0.28 | 1.38 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 32.32 | 95.49 |
Price Performance
Historical ComparisonAbout ACDC ProFrac Holding Corp.
ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.